The nature of the HIV epidemic and the subsequent diagnostic demand are highly non-uniform across the United States, making a detailed understanding of the US HIV Diagnostics Market Regional Share essential for effective commercial and public health planning. The market share and overall testing volume are disproportionately concentrated in specific metropolitan areas and states identified as high-priority jurisdictions under the "Ending the HIV Epidemic in the U.S." (EHE) initiative. These regions, which include major urban centers with historically high HIV prevalence and incidence, account for the majority of advanced molecular testing for viral load monitoring and the highest deployment of targeted community-based rapid testing.

Analysis of the US HIV Diagnostics Market Regional Share reveals that the Western and Northeastern states, particularly those with strong public health infrastructure and early adoption of progressive testing policies (like opt-out screening), represent the highest-value markets for both instruments and consumables. Conversely, the Southern states, which are often cited for having some of the highest new infection rates, represent a significant high-growth opportunity, provided that market players can navigate access barriers and the specific challenges of reaching rural populations. Strategic players must therefore tailor their sales and distribution networks to match this regional concentration, focusing intensive sales support and high-end equipment placement in the major urban centers, while deploying cost-effective, decentralized point-of-care solutions to expand testing access throughout the emerging, high-need regional markets.